Entera Bio Ltd. Logo

Entera Bio Ltd.

Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.

ENTX | US

Overview

Corporate Details

ISIN(s):
IL0011429839
LEI:
Country:
United States of America
Address:
KIRYAT HADASSAH, MINRAV BUILDING, 9112002 JERUSALEM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Entera Bio Ltd. is a clinical-stage biopharmaceutical company specializing in the development of orally delivered large molecule and peptide therapeutics. The company's proprietary N-Tab™ technology platform enables the oral administration of drugs that are typically injectable by stabilizing the active ingredients in the gastrointestinal tract and enhancing absorption. Entera's primary focus is on therapies for significant unmet medical needs. Its clinical pipeline is led by EB613, an oral parathyroid hormone (PTH) tablet for postmenopausal women with osteoporosis, and EB612 for patients with hypoparathyroidism. The company is also developing oral treatments for obesity and rare malabsorption conditions like short bowel syndrome.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Entera Bio Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Entera Bio Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Entera Bio Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany
VVY
VivoSim Labs, INC. Logo
Offers 3D human tissue models for predictive toxicology testing to accelerate drug discovery.
United States of America
VIVS
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea
082800
VOLITIONRX LTD Logo
Develops epigenetic blood tests for early cancer and sepsis detection in human/veterinary markets.
United States of America
VNRX
vTv Therapeutics Inc. Logo
Develops oral small molecule drugs for type 1 diabetes and other chronic conditions.
United States of America
VTVT
VYNE Therapeutics Inc. Logo
Clinical-stage biopharma developing novel therapies for immuno-inflammatory diseases.
United States of America
VYNE
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan
4512
Wave Life Sciences Ltd. Logo
Developing RNA-based medicines for severe genetic diseases like DMD and Huntington's disease.
United States of America
WVE
WELLBIOTEC CO.,LTD Logo
Diversified in biopharma, EV chargers, and lithium supply for batteries.
South Korea
010600
Werewolf Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies for a localized immune attack on cancer.
United States of America
HOWL

Talk to a Data Expert

Have a question? We'll get back to you promptly.